Please activate JavaScript!
Please install Adobe Flash Player, click here for download

implants - international magazine of oral implantology

2_2016 14 debilitante, si sono fatti grandi passi avanti nella sua cura e prevenzione. Per questo, non si può più pensare di evitare i trattamenti nei pazienti in cura con farmaci associati alla ONJ. È compito di tutti gli odontoiatri e professionisti della salute orale assicurare un’efficace comunicazione con il paziente e una valida collaborazione con i medici prescrittori al fine di prevenire tutte le compli- canze legate all’osteonecrosi delle ossa mascel- lari, che possono e devono essere al più evitate. Se si crede che l’odontoiatria sia una disciplina importante per la salute generale del paziente, l’odontoiatra non può non fare la sua parte al servizio della sanità generale. 1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7. 2. Ministero della salute: Raccomandazioni per la pro- mozione della salute orale, la prevenzione delle pa- tologie orali e la terapia odontostomatologica nei pazienti adulti con malattia neoplastica. http://www. salute.gov.it/imgs/C_17_pubblicazioni_2139_allega- to.pdf. 3. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Agha- loo T, Mehrotra B, O’Ryan F; American Association of Oral and Maxillofacial Surgeons. American Associa- tion of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938- 56. doi: 10.1016/j.joms.2014.04.031. 4. Kyrgidis, A. and Toulis, K. A. (2010): Denosumab-rela- ted osteonecrosis of the jaws. Osteoporos Int 22(1): 369-370. 5. Stopeck, A.T., Lipton, A., et al. (2010): Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35): 5132-5139. 6. Saad, F., Brown. J. E., et al. (2012): Incidence, risk fac- tors, and outcomes of osteonecrosis of the jaw: inte- grated analysis from three blinded active-controlled phase III trials in cancer patients with bone metasta- ses. Ann Oncol 23(5): 1341-7. 7. AIFA (2010-a): Nota informava importante su Avastin (bevacizumab) del 30/11/2010. http://www.agenzia- farmaco.gov.it/it/content/nota-informativa-impor- tante-su-avastin-bevacizumab-del-30112010. 8. Brunello, A., Saia, G., et al. (2009): Worsening of oste- onecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 44(1): 173- 175. 9. AIFA (2010-b): Nota informava importante sul Suniti- nib (Sutent) del 30/11/2010. http:// www.agenziafar- maco.gov.it/it/content/nota-informa va-importante- sul-sunitinib-sutent-del-30112010. 10. Giancola F, Campisi G, Lo Russo L, Muzio LL, Di Fede O. Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report? Ann Stomatol (Roma). 2013 Oct 24;4(Suppl 2):20-1.eCollection 2013. PubMed PMID: 24353782;PubMed Central PMCID: PMC3860225. 11. Bedogni A., Campisi G., Fusco V., Agrillo A. Raccoman- dazioni clinico-terapeutiche sull’osteonecrosi delle ossa mascellari associata a bisfosfonati e sua preven- zione. SICMF – SIPMO. 2013. 12. Fedele, S., Kumar, N., et al. (2009): Dental manage- ment of patients at risk of osteochemonecrosis of the jaws: a critical review. Oral Dis 15(8): 527-537. 13. Ruggiero, S. L., Dodson, T. B., et al. (2009): American Association of Oral and Maxillofacial Surgeons posi- tion paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 67(5 Suppl): 2-12. 14. Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Be- dogni A. Epidemiology, clinical manifestations, risk re- duction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol. 2014 Feb;10(2):257-75. doi: 10.2217/ fon.13.211. Review. PubMed PMID: 24490612. 15. Dodson TB. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors. Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):509-16. doi: 10.1016/j.coms.2015.06.003. Epub 2015 Sep 9. Review. PubMed PMID: 26362367. 16. Kyrgidis, A., Teleioudis, Z., et al. (2010): The role of dental hygienist in the preven on of osteonecrosis of the jaw in patients wearing dentures. Int J Dent Hyg 8(2): 154. 17. Scully, C., Kumar, N., et al. (2010): Hot topics in special care dentistry: 9. Bisphosphonates. Dent Update 37(1): 63. 18. Pemberton, M. N. (2010): Osteonecrosis of the jaw. Note on dental procedures. BMJ 340: c1317. 19. Lodi G, Sardella A, Salis A, Demarosi F, Tarozzi M, Car- rassi A. Tooth extraction in patients taking intrave- nous bisphosphonates: a preventive protocol and case series. J Oral Maxillofac Surg. 2010 Jan;68(1):107-10. 20. Scoletta M, Arduino PG, Pol R, Arata V, Silvestri S, Chiecchio A, Mozzati M. Initial experience on the outcome of teeth extractions in intravenous bispho- sphonate-treated patients: a cautionary report. J Oral Maxillofac Surg. 2011 Feb;69(2):456-62. 21. Protocollo PROMaF (Prevenzione e Ricerca sull’O- steonecrosi delle Ossa Mascellari da Farmaci). Di- cembre 2014. http://www.policlinico.pa.it/portal/ pdf/news/2014/PROMaF/PROMaFxOperatoriSanitari- dic2014.pdf. 22. C Bedogni A, Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A, Bettini G, Di Fede O, Oteri G, Fusco V, Gabriele M, Ottolenghi L, Valsecchi S, Porter S, Petruzzi M, Arduino P, D’Amato S, Ungari C, Fung Polly PL, Saia G, Campisi G. Staging of osteonecrosis of the jaw requires computed tomography for accu- rate definition of the extent of bony disease. Br J Oral Maxillofac Surg.2014 Sep;52(7):603-8. doi: 10.1016/j. bjoms.2014.04.009. Epub 2014 May 22. PubMed PMID: 24856927. 23. Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A, Bettini G, Di Fede O, Oteri G, Fusco V, Ga- briele M, Ottolenghi L, Valsecchi S, Porter S, Fung PP, Saia G, Campisi G, Bedogni A. Up to a quarter of pa- tients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg. 2015 Jan;53(1):13-7. doi: 10.1016/j. bjoms.2014.09.001. Epub 2014 Oct 2. PubMed PMID: 25282593. _bibliografia special _ ONJ

Sito